A study of HBV-associated liver cancer showed that CCR4+ Treg were predominantly infiltrated in HBV+ tumor tissue, which expressed IL-10 and IL-35 more than CCR4− Treg and was more potent at suppressing CD8+ T-cells, which led to resistance to sorafenib. Here, CD8A is linked to liver cancer.